TQ-A3334 not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · AL-034
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chronic Hepatitis B
- Main trialPhase 2
- “This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.”In the company’s words, NCT06706310 on ClinicalTrials.gov
- Other names
- AL-034
Other drugs for Chronic Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 7 Dec 2025 | Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection | |
| Phase 1/2Terminated | 25 Aug 2023 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | |
| Phase 1Completed | 14 Nov 2018 | A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants | |
| Phase 1Completed | 24 Jun 2024 | A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026